Characterization molecular and immunologic features of CML stem cells for treatment-free remission.

• Project/Area Number: 18K08375
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 54010:Hematology and medical oncology-related
• Research Institution: Kindai University
• Principal Investigator: MATSUMUTA Itaru 近畿大学, 医学部, 教授 (00294083)
• Co-Investigator(Kenkyū-buntansha): 田中 宏和 近畿大学, 医学部, 准教授 (40360846) ; 頼 晋也 近畿大学, 医学部, 講師 (70460855) ; 森田 泰慶 近畿大学, 医学部, 講師 (80411594)
• Project Period (FY): 2018-04-01 – 2021-03-31
• Project Status: Completed (Fiscal Year 2020)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2020: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2019: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000); Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
• Keywords: 慢性骨髄性白血病 / 分子標的 / 腫瘍免疫 / アミノ酸代謝 / CML / CML幹細胞 / チロシンキナーゼ阻害薬 / 免疫チェックポイント分子

Outline of Final Research Achievements

In this study, we analyzed immune evasion mechanisms of residual chronic myeloid leukemia stem cells　(CML-LSCs) during the treatment with tyrosine kinase inhibitors (TKIs). Both expression of immune checkpoint molecule, PDL1 and activation of immunosuppressive enzyme, IDO1 were induced through the activation of CD120a/NF-κB signaling pathway in phenotypically defined CD34+38-120a+225+ cells, which we previously identified as CML-LSC. Furthermore, CML-LSCs suppressed cytotoxic T cell activity and induced a local recruitment of immunosuppressive populations such as regulatory T cells and myeloid-derived suppressor cells, leading to an immunosuppressive bone marrow milieu undergoing TKI therapy.

Academic Significance and Societal Importance of the Research Achievements

本研究は、CMLの免疫回避機構における腫瘍免疫とアミノ酸代謝との関連を明らかにしたものであり学術的意義は高い。本研究により、組織内IDO1活性を指標としたTKI の中止可能な症例の選別法だけでなく、治癒に向けたIDO1阻害によるCML-LSCに対する新規治療法を開発する上で、重要な知見が得られたと考えられる。

Research Products

• [Journal Article] Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. (2021)
  • Author(s): Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito AM, Hirakawa A, Kiyoi H, Matsumura I, Miyazaki Y
  • Journal Title: Int J Hematol. Volume: 113 Issue: 3 Pages: 395-403
  • DOI: 10.1007/s12185-020-03032-3
  • Peer Reviewed / Open Access
• [Journal Article] The Impact of Hemodialysis and Liver Cirrhosis on the Plasma Concentrations of Tyrosine Kinase Inhibitors in a Patient with Chronic Myeloid Leukemia (2020)
  • Author(s): Taniguchi Y, Takahashi N, Miura M, Hirase C, Sueda S, Espinoza JL, Rai S, Nakayama S, Serizawa K, Kumode T, Watatani Y, Morita Y, Tanaka H, Matsumura I.
  • Journal Title: Internal Medicine Volume: 59 Issue: 21 Pages: 2745-2749
  • DOI: 10.2169/internalmedicine.4871-20
  • NAID: 130007934222
  • ISSN: 0918-2918, 1349-7235
  • Year and Date: 2020-11-01
  • Peer Reviewed / Open Access
• [Journal Article] Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature. (2020)
  • Author(s): Takeshita A, Asou N, Atsuta Y, Furumaki H, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Minamiguchi H, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y.
  • Journal Title: Cancers (Basel) Volume: 12(6) Issue: 6 Pages: 1444-1444
  • DOI: 10.3390/cancers12061444
  • Peer Reviewed / Open Access
• [Journal Article] Treatment outcomes of chronic-phase chronic myeloid leukemia with resistance and/or intolerance to a 1st-line tyrosine kinase inhibitor in Japan: the results of the New TARGET study 2nd-line (2020)
  • Author(s): Sakurai M, Okamoto S, Matsumura I, Murakami S, Takizawa M, Waki M, Hirano D, Watanabe-Nakaseko R, Kobayashi N, Iino M, Mitsui H, Ishikawa Y, Takahashi N, Kawaguchi T, Suzuki R, Yamamoto K, Kizaki M, Ohnishi K, Naoe T, Akashi K; New TARGET investigators.
  • Journal Title: Int J Hematol. Volume: 111 Issue: 6 Pages: 912-825
  • DOI: 10.1007/s12185-020-02843-8
  • Peer Reviewed / Open Access
• [Journal Article] Prognostic effect of comorbidities in patients with chronic myeloid leukemia treated with a tyrosine kinase inhibitor (2020)
  • Author(s): Ono Takaaki、Takahashi Naoto、Kizaki Masahiro、Kawaguchi Tatsuya、Suzuki Ritsuro、Yamamoto Kazuhito、Ohnishi Kazunori、Naoe Tomoki、Matsumura Itaru
  • Journal Title: Cancer Science Volume: 111 Issue: 10 Pages: 3714-3725
  • DOI: 10.1111/cas.14580
  • Peer Reviewed / Open Access
• [Journal Article] Phase 2 study of bosutinib in Japanese patients with newly diagnosed chronic phase chronic myeloid leukemia. (2020)
  • Author(s): Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, Sekiguchi N, Tanetsugu Y, Fukuhara K, Ohkura M, Koide Y, Takahashi N.
  • Journal Title: International Journal of Hematology Volume: Epub ahead of print Issue: 1 Pages: 24-32
  • DOI: 10.1007/s12185-020-02878-x
  • NAID: 120007036312
  • Peer Reviewed / Open Access
• [Journal Article] Chlorpromazine eliminates acute myeloid leukemia cells by perturbing subcellular localization of FLT3-ITD and KIT-D816V. (2020)
  • Author(s): Shinya Rai, Hirokazu Tanaka*, Mai Suzuki, J. Luis Espinoza, Takahiro Kumode, Akira Tanimura, Yasuyoshi Morita, Yoichi Tatsumi, Takafumi Yokota, Kenji Oritani, Toshio Watanabe, Yuzuru Kanakura, and Itaru Matsumura.
  • Journal Title: Nature Communications Volume: 11 Issue: 1 Pages: 4147-4147
  • DOI: 10.1038/s41467-020-17666-8
  • Peer Reviewed / Open Access
• [Journal Article] Tamibarotene maintenance improved relapse-free survival of acute promyelocytic leukemia: a final result of prospective, randomized, JALSG-APL204 study. (2019)
  • Author(s): Takeshita A, Asou N, Atsuta Y, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Furumaki H, Obata Y, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y
  • Journal Title: Leukemia Volume: 33 Issue: 2 Pages: 358-370
  • DOI: 10.1038/s41375-018-0233-7
  • Peer Reviewed / Open Access
• [Journal Article] Antidiuretic hormone‐ and interleukin‐6‐producing angioimmunoblastic T‐cell lymphoma associated with syndrome of inappropriate antidiuretic hormone secretion (2019)
  • Author(s): Taniguchi Takahide、Nakayama Shoko、Morita Yasuyoshi、Rai Shinya、Espinoza Jorge L.、Matsumura Itaru
  • Journal Title: British Journal of Haematology Volume: 184 Issue: 2 Pages: 121-121
  • DOI: 10.1111/bjh.15689
  • Peer Reviewed / Open Access
• [Journal Article] Severe Eosinophilia in Myelodysplastic Syndrome With a Defined and Rare Cytogenetic Abnormality (2019)
  • Author(s): Rai Shinya、Espinoza J. Luis、Morita Yasuyoshi、Tanaka Hirokazu、Matsumura Itaru
  • Journal Title: Frontiers in Immunology Volume: 9
  • DOI: 10.3389/fimmu.2018.03031
  • Peer Reviewed
• [Journal Article] Excessive Reactive Iron Impairs Hematopoiesis by Affecting Both Immature Hematopoietic Cells and Stromal Cells (2019)
  • Author(s): Tanaka Hirokazu、Espinoza J.、Fujiwara Ryosuke、Rai Shinya、Morita Yasuyoshi、Ashida Takashi、Kanakura Yuzuru、Matsumura Itaru
  • Journal Title: Cells Volume: 8 Issue: 3 Pages: 226-226
  • DOI: 10.3390/cells8030226
  • Peer Reviewed / Open Access
• [Journal Article] Multiple cytokine-producing B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classic Hodgkin lymphoma with autoimmune hemolytic anemia (2019)
  • Author(s): Nakayama Shoko、Morita Yasuyoshi、Espinoza Jorge Luis、Rai Shinya、Oyama Yasuyo、Taniguchi Takahide、Miyake Yoshiaki、Tanaka Hirokazu、Matsumura Itaru
  • Journal Title: Leukemia & Lymphoma Volume: 60 Issue: 2 Pages: 1-3
  • DOI: 10.1080/10428194.2019.1665665
  • Peer Reviewed / Open Access
• [Journal Article] Efficacy and safety of tyrosine kinase inhibitors for newly diagnosed chronic-phase chronic myeloid leukemia over a 5-year period: results from the Japanese registry obtained by the New TARGET system. (2019)
  • Author(s): Kizaki M, Takahashi N, Iriyama N, Okamoto S, Ono T, Usui N, Inokuchi K, Nakaseko C, Kurokawa M, Sumi M, Nakamura F, Kawaguchi T, Suzuki R, Yamamoto K, Ohnishi K, Matsumura I, Naoe T; New TARGET investigators.
  • Journal Title: Int J Hematol Volume: 109 Issue: 4 Pages: 426-439
  • DOI: 10.1007/s12185-019-02613-1
  • Peer Reviewed / Open Access
• [Journal Article] Cessation of nilotinib in patients with chronic myelogenous leukemia who have maintained deep molecular responses for 2 years: a multicenter phase 2 trial, stop nilotinib (NILSt). (2019)
  • Author(s): Nagafuji K, Matsumura I, Shimose T, Kawaguchi T, Kuroda J, Nakamae H, Miyamoto T, Kadowaki N, Ishikawa J, Imamura Y, Yamazaki H, Akashi K, Kanakura Y.
  • Journal Title: Int J Hematol Volume: 110 Issue: 6 Pages: 675-682
  • DOI: 10.1007/s12185-019-02736-5
  • Peer Reviewed / Open Access
• [Journal Article] Classic Hodgkin Lymphoproliferative Diseases Clonally Unrelated to B-Chronic Lymphocytic Leukemia Successfully Treated with Bendamustine Plus Rituximab. (2018)
  • Author(s): Rai S, Tanaka H, Fujimoto K, Kumode T, Inoue H, Taniguchi Y, Morita Y, Espinoza JL, Tatsumi Y, Ashida T, Matsuoka R, Kikuti YY, Nakamura N, Matsumura I.
  • Journal Title: Cancers (Basel). Volume: 10 Issue: 9 Pages: 304-304
  • DOI: 10.3390/cancers10090304
  • NAID: 120007133039
  • Peer Reviewed / Open Access
• [Journal Article] Retrospective analysis of primary plasma cell leukemia in Kansai Myeloma Forum registry (2018)
  • Author(s): Nakaya A, Yagi H, Kaneko H, Kosugi S, Kida T, Adachi Y, Shibayama H, Kohara T, Kamitsuji Y, Fuchida SI, Uoshima N, Kawata E, Uchiyama H, Shimura Y, Takahashi T, Urase F, Ohta K, Hamada T, Miyamoto K, Kobayashi M, Shindo M, Tanaka H, Shimazaki C, Hino M, Kuroda J, Kanakura Y, Takaoari-Kondo A, Nomura S, Matsumura I
  • Journal Title: Leukemia Research Reports Volume: 10 Pages: 7-10
  • DOI: 10.1016/j.lrr.2018.07.001
  • Peer Reviewed / Open Access
• [Journal Article] Five-day regimen of azacitidine for lower-risk myelodysplastic syndromes (refractory anemia or refractory anemia with ringed sideroblasts): A prospective single-arm phase 2 trial (2018)
  • Author(s): Morita Yasuyoshi、Maeda Yasuhiro、Yamaguchi Terufumi、Urase Fumiaki、Kawata Shuhei、Hanamoto Hitoshi、Tsubaki Kazuo、Ishikawa Jun、Shibayama Hirohiko、Matsumura Itaru、Matsuda Mitsuhiro
  • Journal Title: Cancer Science Volume: 109 Issue: 10 Pages: 3209-3215
  • DOI: 10.1111/cas.13739
  • Peer Reviewed / Open Access
• [Journal Article] Tumor necrosis factor- and interleukin-6-producing high-grade B-cell lymphoma, not otherwise specified in the pleura (2018)
  • Author(s): Nakayama Shoko、Matsuda Mitsuhiro、Adachi Tatsuya、Sueda Sanae、Ueda Kayo、Kawahara Kunimitsu、Ohashi Yuka、Awaji Sumie、Hashimoto Shigeo、Matsumura Itaru
  • Journal Title: Leukemia Research Reports Volume: 10 Pages: 1-3
  • DOI: 10.1016/j.lrr.2018.06.001
  • Peer Reviewed / Open Access
• [Journal Article] Immunemodulatory Effects of 5-Azacitidin Through Expansion of Functional Regulatory T Cells on Paraneoplastic Inflammation Associated With Myelodysplastic Syndromes: A Case Report (2018)
  • Author(s): Serizawa Kentaro、Tanaka Hirokazu、Morita Yasuyoshi、Taniguchi Takahide、Ashida Takashi、Matsumura Itaru
  • Journal Title: Frontiers in Oncology Volume: 8 Pages: 204-204
  • DOI: 10.3389/fonc.2018.00204
  • Peer Reviewed / Open Access
• [Journal Article] Infectious complications in adults undergoing intensive chemotherapy for acute myeloid leukemia in 2001-2005 using the Japan Adult Leukemia Study Group AML201 protocols. (2018)
  • Author(s): Kato H, Fujita H, Akiyama N, Kimura SI, Hiramoto N, Hosono N, Takahashi T, Shigeno K, Minamiguchi H, Miyatake J, Handa H, Kanda Y, Yoshida M, Miyawaki S, Ohtake S, Naoe T, Kiyoi H, Matsumura I, Miyazaki Y
  • Journal Title: Support Care Cancer Volume: 26 Issue: 12 Pages: 4187-4198
  • DOI: 10.1007/s00520-018-4292-0
  • Peer Reviewed / Open Access
• [Journal Article] Adult T cell leukemia/lymphoma with different pathological features in each tumor site (2018)
  • Author(s): Nakayama Shoko、Matsuda Mitsuhiro、Adachi Tatsuya、Sueda Sanae、Ohashi Yuka、Awaji Sumie、Hashimoto Shigeo、Matsumura Itaru
  • Journal Title: Annals of Hematology Volume: 97 Issue: 6 Pages: 1095-1096
  • DOI: 10.1007/s00277-018-3272-2
  • Peer Reviewed / Open Access
• [Journal Article] Management of cardiovascular complications in CML patients treated with tyrosine kinase inhibitors (2018)
  • Author(s): 松村 到
  • Journal Title: Rinsho Ketsueki Volume: 59 Issue: 1 Pages: 13-26
  • DOI: 10.11406/rinketsu.59.13
  • NAID: 130006337957
  • ISSN: 0485-1439, 1882-0824
  • Peer Reviewed / Open Access
• [Journal Article] Pomalidomide with or without dexamethasone for relapsed/refractory multiple myeloma in Japan: a retrospective analysis by the Kansai Myeloma Forum (2018)
  • Author(s): Matsumura-Kimoto Y, Kuroda J, Kaneko H, Kamitsuji Y, Fuchida SI, Nakaya A, Shibayama H, Uoshima N, Yokota I, Uchiyama H, Yagi H, Kosugi S, Matsui T, Ishikawa J, Matsuda M, Ohta K, Iida M, Tanaka H, Kobayashi M, Wada K, Shimazaki C, Nomura S, Imada K, Hino M, Matsumura I, Kanakura Y, Takaori-Kondo A; KMF
  • Journal Title: International Journal of Hematology Volume: 107 Issue: 5 Pages: 541-550
  • DOI: 10.1007/s12185-018-2416-4
  • Peer Reviewed / Open Access
• [Journal Article] Efficacy and safety of switching to nilotinib in patients with CML-CP in major molecular response to imatinib: results of a multicenter phase II trial (NILSw trial) (2018)
  • Author(s): Ishikawa Jun、Matsumura Itaru、Kawaguchi Tatsuya、Kuroda Junya、Nakamae Hirohisa、Miyamoto Toshihiro、Matsuoka Ken-ichi、Shibayama Hirohiko、Hino Masayuki、Hirase Chikara、Kamimura Tomohiko、Shimose Takayuki、Akashi Koichi、Kanakura Yuzuru
  • Journal Title: International Journal of Hematology Volume: 107 Issue: 5 Pages: 535-540
  • DOI: 10.1007/s12185-018-2401-y
  • Peer Reviewed
• [Journal Article] Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study (2018)
  • Author(s): Harada Y、Nagata Y、Kihara R、Ishikawa Y、Asou N、Ohtake S、Miyawaki S、Sakura T、Ozawa Y、Usui N、Kanamori H、Ito Y、Imai K、Suehiro Y、Kobayashi S、Kitamura K、Sakaida E、Onizuka M、Takeshita A、Ishida F、Suzushima H、Ishizawa K、Naoe T、Matsumura I、Miyazaki Y、Ogawa S、Kiyoi H
  • Journal Title: Leukemia Research Volume: 66 Pages: 20-27
  • DOI: 10.1016/j.leukres.2018.01.008
  • NAID: 120006473597
  • Peer Reviewed
• [Journal Article] Nilotinib vs. imatinib in Japanese patients with newly diagnosed chronic myeloid leukemia in chronic phase: long-term follow-up of the Japanese subgroup of the randomized ENESTnd trial (2017)
  • Author(s): Nakamae H, Fukuda T, Nakaseko C, Kanda Y, Ohmine K, Ono T, Matsumura I,Matsuda A, Aoki M, Ito K, Shibayama H.
  • Journal Title: Int J Hematol. Volume: 107 Issue: 3 Pages: 327-336
  • DOI: 10.1007/s12185-017-2353-7
  • Peer Reviewed / Open Access
• [Journal Article] Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study (2017)
  • Author(s): Takahashi Naoto、Miyata Yasuhiko、Kobayashi Shinichi、Usuki Kensuke、Matsumura Itaru、Minami Yosuke、Usui Noriko、Fukuda Tetsuya、Kobayashi Yukio、Kiyoi Hitoshi、et al.
  • Journal Title: Int J Hematol Volume: 107 Issue: 2 Pages: 185-193
  • DOI: 10.1007/s12185-017-2334-x
  • Peer Reviewed / Open Access
• [Presentation] Nilotinib Vs. Dasatinib in Achieving MR4.5 for Newly Diagnosed Chronic Myeloid Leukemia: Results of the Prospective Randomized Phase 3 Study, JALSG CML212 (2020)
  • Author(s): Matsumura I, Ohtake S, Atsuta Y , et al.
  • Organizer: 62th ASH Annual Meeting and Exposition
  • Int'l Joint Research
• [Presentation] ASXL1 Mutations Predict a Poor Response to Darbepoetin Alfa in Anemic Patients with Low-Risk MDS: A Multicenter, Phase II Study (2020)
  • Author(s): Hanamoto H, Morita Y, Matsumura I, et al.
  • Organizer: 62th ASH Annual Meeting and Exposition
  • Int'l Joint Research
• [Presentation] CML治療の現状と今後 (2020)
  • Author(s): 松村 到
  • Organizer: 第82回日本血液学会学術集会
• [Presentation] Infiltration of effector regulatory T cells is associated with poor prognosis in diffuse large B-cell lymphoma, not otherwise specified (2019)
  • Author(s): Nakayama S,Tanaka H, Luis Espinoza, Morita Y, Shinya Rai, Itaru Matsumura
  • Organizer: The 10th JSH International Symposium 2019 in Ise-Shima
  • Int'l Joint Research
• [Presentation] 慢性骨髄性白血病治療の進歩 (2019)
  • Author(s): 松村到
  • Organizer: 第57回日本癌治療学会学術集会
• [Presentation] BCR-ABLINS35bpはCMLの長期予後に悪影響を与えない：新ターゲット観察研究1 (2019)
  • Author(s): 山本 一仁, 高橋 直人, 湯田 淳一朗, 木崎 昌弘, 川口 辰哉, 鈴木 律朗, 大西 一功, 直江 知樹, 松村 到
  • Organizer: 第81回日本血液学会学術集会
• [Presentation] 新TARGET観察研究1における高齢者慢性骨髄性白血病の予後解析 (2019)
  • Author(s): 小野 孝明, 高橋 直人, 木崎 昌弘, 川口 辰哉, 鈴木 律朗, 山本 一仁, 大西 一功, 直江 知樹, 松村 到
  • Organizer: 第81回日本血液学会学術集会
• [Presentation] チャールソン併存疾患指数が慢性骨髄性白血病の予後に与える影響―新TARGET観察研究1 (2019)
  • Author(s): 小野 孝明, 高橋 直人, 木崎 昌弘, 川口 辰哉, 鈴木 律朗, 山本 一仁, 大西 一功, 直江 知樹, 松村 到
  • Organizer: 第81回日本血液学会学術集会
• [Presentation] 第2世代TKIは初診時付加的染色体異常を有するCMLの予後を改善し得る：新TARGET観察研究 1 (2019)
  • Author(s): 吉岡 智子, 高橋 直人, 木崎 昌弘, 川口 辰哉, 鈴木 律朗, 山本 一仁, 大西 一功, 直江 知樹, 松村 到
  • Organizer: 第81回日本血液学会学術集会
• [Presentation] In vitro safety and efficacy of S888711, a novel thrombopoietin receptor agonist, in Myelodysplastic syndrome (2018)
  • Author(s): Keigo Sano, Hirokazu Tanaka, Itaru Matsumura
  • Organizer: 第1回国際がん研究シンポジウム
  • Int'l Joint Research
• [Presentation] 症候性骨髄腫1414例の後方視的解析：関西骨髄腫フォーラムからの最新報告 (2018)
  • Author(s): 田中 宏和, 芹澤 憲太郎, 中谷 綾, 金子 仁臣, 太田 健介, 小杉 智, 八木 秀男, 花本 仁, 淵田 真一, 志村 勇司, 柴山 浩彦, 小原 尚恵, 中谷 英仁, 諫田 淳也, 魚嶋 伸彦, 和田 勝也, 烏野 隆博, 松井 利充, 内山 人二, 松田 光弘, 足立 陽子, 高折 晃史, 黒田 純也, 谷脇 雅史, 島崎 千尋, 日野 雅之, 今田 和典, 野村 昌作, 金倉 譲, 松村 到
  • Organizer: 第80回日本血液学会学術集会
• [Presentation] 造血器腫瘍における治療標的としてのチロシンキナーゼ (2018)
  • Author(s): 松村 到
  • Organizer: 第80回日本血液学会学術集会
• [Presentation] CD34陽性ヒト骨髄腫幹細胞の同定と特性解析 (2018)
  • Author(s): 芹澤 憲太郎, 田中 宏和, 福井 彩乃, 藤原 亮介, 佐野 圭吾, 口分田 貴裕, 谷口 康博, 森田 泰慶, ルイス エスピノザ, 辰巳 陽一, 芦田 隆司, 松村 到
  • Organizer: 第80回日本血液学会学術集会
• [Presentation] 異常なRTKの細胞内輸送阻害は急性骨髄性白血病における有望な治療標的である。 (2018)
  • Author(s): 頼 晋也 田中 宏和, 鈴木 麻衣, Luis Espinoza, 谷村 朗, 森田 泰慶, 辰巳 陽一, 横田 貴史, 織谷 健司, 渡邊 俊雄, 金倉 譲, 松村 到
  • Organizer: 第80回日本血液学会学術集会